Amber Bio

Amber Bio is a San Francisco-based biotechnology company founded in 2021 that is pioneering RNA-based gene editing. Its multi-kilobase RNA writing platform is designed to correct thousands of diverse mutations across a patient population with a single product, rather than requiring an independent therapy for each separate mutation. The company positions the approach as safe (minimal off-target effects), reversible, and capable of edits far larger than conventional base or prime editing, targeting previously undruggable genetic disease populations. Amber Bio launched publicly in August 2023 with an oversubscribed $26M seed round co-led by Playground Global and Andreessen Horowitz Bio + Health. It is a pre-clinical therapeutics company and publishes no public API, developer portal, or SDK surface.

Amber Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Gene Editing, RNA, and Therapeutics.

Amber Bio’s developer surface includes product news and 8 more developer resources.

🌐 Visit website 📡 Source on GitHub

7.7/100 minimal ▬ flat Agent 4/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyGene EditingRNATherapeuticsLife SciencesPrecision MedicinePre-Clinical

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 7.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 4/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 4 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/amber: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

WellKnown

WellKnown

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 5

The organization behind the API

Website

About

News

Careers

LinkedIn

Other 1

Properties that don't map to a standard resource type

Team

Team

Source (apis.yml)

aid: amber
name: Amber Bio
description: Amber Bio is a San Francisco-based biotechnology company founded in 2021 that is pioneering RNA-based gene editing.
  Its multi-kilobase RNA writing platform is designed to correct thousands of diverse mutations across a patient population
  with a single product, rather than requiring an independent therapy for each separate mutation. The company positions the
  approach as safe (minimal off-target effects), reversible, and capable of edits far larger than conventional base or prime
  editing, targeting previously undruggable genetic disease populations. Amber Bio launched publicly in August 2023 with an
  oversubscribed $26M seed round co-led by Playground Global and Andreessen Horowitz Bio + Health. It is a pre-clinical therapeutics
  company and publishes no public API, developer portal, or SDK surface.
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://cdn.prod.website-files.com/6245f65e49aca16254e8bad8/62472aefc8c77a733e1635a4_Webclip.png
url: https://raw.githubusercontent.com/api-evangelist/amber/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- Playground Global
- Eli Lilly
- Pillar VC
- Hummingbird
- Retinal Degeneration Fund
- SV Angel
x-tier: stub
x-tier-reason: no-public-api-surface
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Gene Editing
- RNA
- Therapeutics
- Life Sciences
- Precision Medicine
- Pre-Clinical
apis: []
common:
- type: DomainSecurity
  url: security/amber-domain-security.yml
- type: Website
  url: https://www.amber.bio/
- type: About
  url: https://www.amber.bio/#about-us
- type: Team
  url: https://www.amber.bio/#team
- type: News
  url: https://www.amber.bio/#news
- type: Careers
  url: https://www.amber.bio/careers
- type: LinkedIn
  url: https://www.linkedin.com/company/amber-bio
- type: WellKnown
  url: well-known/amber-well-known.yml
- type: LLMsTxt
  url: llms/amber-llms.txt
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: minimal
  artifacts_added: 3
  pass: local-v1
  note: 'Stub resolved to Amber Bio (amber.bio) — the a16z Bio + Health seed co-lead. Pre-clinical RNA gene-editing therapeutics
    company with a single-page Webflow marketing site and a /careers page. No API, developer portal, docs, SDK, package, event,
    GitHub organization, or .well-known surface exists; the DX/runtime-semantics tier is genuinely N/A rather than missing.
    Probes: all /.well-known/* and /llms.txt 404; no vulnerability-disclosure program and no trust center; TLS 1.3 + HSTS
    present, DNSSEC and CAA absent, SPF and DMARC present (dmarc policy none). Site-footer Privacy Policy and Terms of Service
    are dead "#" anchors, so no pointers were emitted for them. Do not re-queue for API artifact enrichment unless the company
    ships a developer surface.'